Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco counties, 2007

Journal of Urban Health

Volumn 87, Issue 4, 2010, Pages 543-552

  Cooper, Erin N ^a   Dodson, Chaka ^a   Stopka, Thomas J ^b   Riley, Elise D ^c   Garfein, Richard S ^d   Bluthenthal, Ricky N ^a,e  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b Office of AIDS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e RAND CORPORATION   (United States)

Author keywords

Evaluation; HIV; Pharmacy; Policy; Sterile syringe access; Viral hepatitis

Indexed keywords

ARTICLE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACY; PREVENTIVE HEALTH SERVICE; STATISTICS; SUBSTANCE ABUSE; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; COMMUNITY PHARMACY SERVICES; HEALTH CARE SURVEYS; HEPATITIS C; HIV INFECTIONS; HUMANS; LOS ANGELES; NEEDLE-EXCHANGE PROGRAMS; SAN FRANCISCO; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77954656937     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-010-9483-z     Document Type: Article

References (26)

1. Armstong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States: 1999 through 2002. Ann Intern Med. 2006;144:705-714.
2. CDC. HIV prevelance estimates-United States, 2006. MMWR. 2008;57(39):1073-1076.
3. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39.
4. CDC. New attitudes & strategies: a comprehensive approach to preventing blood-borne infections among IDUs. Atlanta: Centers for Disease Control and Prevention; 2000.
5. US Public Health Service. HIV Prevention Bulletin: Medical Advice for Persons Who Inject Illicit Drugs. Atlanta, GA: US Department of Health and Human Services; 1997.
6. Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? J Acquir Immune Defic Syndr. 1998;18(Suppl 1):S45-S51.
7. Taussig JA, Weinstein B, Burris S, Jones TS. Syringe law and pharmacy regulations are structural constraints on HIV prevention in the U.S. AIDS. 2000;14(Suppl 1):S47-S51.
8. CDC. Syringe exchange programs-United States, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(44):1164-1167.
9. Bluthenthal RN, Heinzerling KG, Anderson R, Flynn NM, Kral AH. Approval of syringe exchange programs in California: results from a local approach to HIV prevention. Am J Public Health. 2008;98(2):278-283.
10. Tempalski B, Friedman R, Keem M, Cooper H, Friedman SR. NIMBY localism and national inequitable exclusion alliances: the case of syringe exchange programs in the United States. Geoforum. 2007;38(6):1250-1263.
11. Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999. J Acquir Immune Defic Syndr. 2001;27:183-192.
12. Fuller C, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007;97(1):117-124.
13. Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State expanded syringe access demonstration program. J Acquir Immune Defic Syndr. 2005;39(4):471-477.
14. Reich W, Compton WM, Horton JC, et al. Pharmacist ambivalence about sale of syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S52-S57.
15. Diebert R, Goldbaum G, Parker T, et al. Increased access to unrestricted pharmacy sale of syringes in Seattle-King County, Washington: structural and individual level changes. Am J Public Health. 2006;96(8):1347-1353.
16. Farley TA, Niccolai LM, Billeter M, Kissinger PJ, Grace M. Attitudes and practices of pharmacy managers regarding needle sales to injection drug users. J Am Pharm Assoc (Wash). 1999;39(1):23-26.
17. Blumenthal W, Springer KW, Jones S, Stark C. Pharmacy student knowledge, attitudes and beliefs about selling syringes to injection drug users. J Am Pharm Assoc. 2002;42(6 Suppl 2)):S34-S39.
18. Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists' decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S40-S45.
19. Stopka T, Garfein R, Ross A, Truax S.R. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health. 2007;84(1):116-125.
20. Epidemiology OoHAa. Key Indicators of Health. Los Angeles: Los Angeles County Department of Public Health; 2007.
21. Lewis BA, Koester SK, Bush TW. Pharmacists' attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S46-S51.
22. Singer M, Baer HA, Scott G, Horowitz S, Weinstein B. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. Public Health Rep. 1998;113(suppl 1):81-89.
23. Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S77-S82.
24. Rose V. Expanding access to syringes. Focus. 2007;22(3):1-4.
25. Coffin PO, Ahern J, Dorris S, Stevenson L, Fuller C, Vlahov D. More pharmacists in high- risk neighborhoods of New York City support selling syringes to injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S62-S67.
26. Finkelstein R, Tiger R, Greenwald R, Mukherjee R. Pharmacy syringe sale practices during the first year of expanded syringe availability in New York City (2001-2002). J Am Pharm Assoc (Wash). 2002;42(6 Suppl 2):S83-S87.